BRPI0908635A2 - composto, composição farmacêutica e método de tratamento de câncer - Google Patents
composto, composição farmacêutica e método de tratamento de câncerInfo
- Publication number
- BRPI0908635A2 BRPI0908635A2 BRPI0908635A BRPI0908635A BRPI0908635A2 BR PI0908635 A2 BRPI0908635 A2 BR PI0908635A2 BR PI0908635 A BRPI0908635 A BR PI0908635A BR PI0908635 A BRPI0908635 A BR PI0908635A BR PI0908635 A2 BRPI0908635 A2 BR PI0908635A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- treatment method
- cancer treatment
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/164,610 | 2008-06-30 | ||
| US12/164,610 US8426430B2 (en) | 2008-06-30 | 2008-06-30 | Quinazoline derivatives |
| PCT/US2009/049182 WO2010002845A2 (en) | 2008-06-30 | 2009-06-30 | Quinazoline derivatives |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BRPI0908635A2 true BRPI0908635A2 (pt) | 2015-10-13 |
| BRPI0908635A8 BRPI0908635A8 (pt) | 2018-12-18 |
| BRPI0908635B1 BRPI0908635B1 (pt) | 2020-09-01 |
| BRPI0908635B8 BRPI0908635B8 (pt) | 2021-05-25 |
Family
ID=41466556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0908635A BRPI0908635B8 (pt) | 2008-06-30 | 2009-06-30 | composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8426430B2 (pt) |
| EP (1) | EP2318378B1 (pt) |
| JP (1) | JP5602729B2 (pt) |
| KR (1) | KR101664503B1 (pt) |
| AU (1) | AU2009267136B2 (pt) |
| BR (1) | BRPI0908635B8 (pt) |
| CA (1) | CA2726040C (pt) |
| CY (1) | CY1114842T1 (pt) |
| DK (1) | DK2318378T3 (pt) |
| ES (1) | ES2442946T3 (pt) |
| HR (1) | HRP20140066T8 (pt) |
| MX (1) | MX2010012692A (pt) |
| MY (1) | MY150493A (pt) |
| NZ (1) | NZ589191A (pt) |
| PH (1) | PH12010502934A1 (pt) |
| PL (1) | PL2318378T3 (pt) |
| PT (1) | PT2318378E (pt) |
| RU (1) | RU2505534C2 (pt) |
| SG (2) | SG10201604677RA (pt) |
| SI (1) | SI2318378T1 (pt) |
| TW (1) | TWI407962B (pt) |
| WO (1) | WO2010002845A2 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9166071B2 (en) | 2009-10-27 | 2015-10-20 | Silicor Materials Inc. | Polarization resistant solar cell design using an oxygen-rich interface layer |
| CN102311438A (zh) * | 2010-06-30 | 2012-01-11 | 和记黄埔医药（上海）有限公司 | 喹唑啉化合物 |
| CN102906086B (zh) * | 2010-06-30 | 2014-02-12 | 和记黄埔医药（上海）有限公司 | 喹唑啉化合物 |
| WO2012000182A1 (en) | 2010-06-30 | 2012-01-05 | Hutchison Medipharma Limited | Quinazoline compounds |
| TWI466888B (zh) * | 2011-05-25 | 2015-01-01 | Hutchison Medipharma Ltd | 喹唑啉化合物 |
| TWI577671B (zh) * | 2011-11-14 | 2017-04-11 | Sunshine Lake Pharma Co Ltd | Aminoquinazoline derivatives and salts thereof and methods of use thereof |
| CN102659692B (zh) | 2012-05-04 | 2014-04-09 | 郑州泰基鸿诺药物科技有限公司 | 双联厄洛替尼及其制备方法 |
| CN102702115A (zh) * | 2012-05-24 | 2012-10-03 | 盛世泰科生物医药技术(苏州)有限公司 | 一种4-氯-7-氟-6-硝基喹唑啉的合成方法 |
| CN102775315A (zh) * | 2012-07-31 | 2012-11-14 | 上海应用技术学院 | 一种间氨基苯乙炔的制备方法 |
| CN103275018B (zh) * | 2013-04-26 | 2016-03-02 | 浙江工业大学 | 4-[3-氯-4-取代苯胺基]-6-取代甲酰氨基喹唑啉类化合物及制备和应用 |
| CN108863951A (zh) * | 2017-05-16 | 2018-11-23 | 和记黄埔医药（上海）有限公司 | 化合物的盐及其晶型 |
| WO2020007219A1 (zh) * | 2018-07-02 | 2020-01-09 | 南京明德新药研发有限公司 | 一种egfr抑制剂的晶型及其制备方法 |
| CN110903253B (zh) * | 2019-12-13 | 2020-12-25 | 西安交通大学医学院第一附属医院 | 一种喹唑啉酮类化合物及其制备方法和应用 |
| CN116917286B (zh) * | 2021-03-26 | 2026-04-28 | 无锡瓴方生物医药科技有限公司 | 6-氨基甲酸酯取代的杂芳环衍生物 |
| US20240382475A1 (en) * | 2021-08-30 | 2024-11-21 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Quinazoline Derivative, Or Preparation Method Therefor And Use Thereof |
| MX2024010283A (es) * | 2022-02-28 | 2024-08-28 | Sironax Ltd | Moduladores rip1, preparaciones y usos de los mismos. |
| CN118834200A (zh) * | 2024-06-27 | 2024-10-25 | 辽宁大学 | 含酰胺结构的4-苯胺基喹唑啉类化合物及其应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9300059D0 (en) * | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| US5430148A (en) * | 1992-03-31 | 1995-07-04 | Agouron Pharmaceuticals, Inc. | Antiproliferative quinazolines |
| JP2994165B2 (ja) * | 1992-06-26 | 1999-12-27 | ゼネカ・リミテッド | キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤 |
| GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| JP3370340B2 (ja) * | 1996-04-12 | 2003-01-27 | ワーナー―ランバート・コンパニー | チロシンキナーゼの不可逆的阻害剤 |
| HRP970371A2 (en) * | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US6235741B1 (en) * | 1997-05-30 | 2001-05-22 | Merck & Co., Inc. | Angiogenesis inhibitors |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| NZ503991A (en) | 1997-11-06 | 2001-11-30 | American Cyanamid Co | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| BRPI0017548B8 (pt) | 1999-02-10 | 2023-05-02 | Astrazeneca Ab | Composto |
| US6943161B2 (en) * | 1999-12-28 | 2005-09-13 | Pharmacopela Drug Discovery, Inc. | Pyrimidine and triazine kinase inhibitors |
| NZ522568A (en) | 2000-06-22 | 2004-12-24 | Pfizer Prod Inc | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| DE10063435A1 (de) | 2000-12-20 | 2002-07-04 | Boehringer Ingelheim Pharma | Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE60214828T2 (de) * | 2001-02-26 | 2007-09-06 | Mcgill University, Montreal | Kombi-moleküle, welche eine inhibierende wirkung auf die signalübertragung und dna-schädigende eigenschaften haben |
| US20040092750A1 (en) * | 2001-03-01 | 2004-05-13 | Tomoyuki Hasegawa | 2-methylindole-4-acetic acid, process for producing the same, and process for producing intermediate therefor |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| DE10204462A1 (de) | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| BR0313059B8 (pt) | 2002-07-29 | 2021-07-27 | Rigel Pharmaceuticals | composto, e, composição farmacêutica |
| PA8603801A1 (es) | 2003-05-27 | 2004-12-16 | Janssen Pharmaceutica Nv | Derivados de la quinazolina |
| US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| GB0321710D0 (en) | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
| JP4503022B2 (ja) | 2003-12-23 | 2010-07-14 | ファイザー・インク | 新規キノリン誘導体 |
| WO2006071079A1 (en) | 2004-12-29 | 2006-07-06 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof |
| KR100735639B1 (ko) * | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
| US20060281712A1 (en) | 2005-06-14 | 2006-12-14 | Chi-Feng Yen | Pyrimidine compounds |
| US20090182140A1 (en) * | 2005-12-02 | 2009-07-16 | Mitsubishi Tanabe Pharma Corporation | Alicyclic Heterocyclic Compound |
| BRPI0717586A2 (pt) | 2006-09-18 | 2013-10-29 | Boehringer Ingelheim Int | Método para tratar câncer apresentando mutações do egfr |
-
2008
- 2008-06-30 US US12/164,610 patent/US8426430B2/en not_active Expired - Fee Related
- 2008-07-04 TW TW097125257A patent/TWI407962B/zh not_active IP Right Cessation
-
2009
- 2009-06-30 DK DK09774296.9T patent/DK2318378T3/da active
- 2009-06-30 CA CA2726040A patent/CA2726040C/en not_active Expired - Fee Related
- 2009-06-30 BR BRPI0908635A patent/BRPI0908635B8/pt not_active IP Right Cessation
- 2009-06-30 PT PT97742969T patent/PT2318378E/pt unknown
- 2009-06-30 PH PH12010502934A patent/PH12010502934A1/en unknown
- 2009-06-30 MY MYPI20105323 patent/MY150493A/en unknown
- 2009-06-30 NZ NZ589191A patent/NZ589191A/xx not_active IP Right Cessation
- 2009-06-30 KR KR1020107025451A patent/KR101664503B1/ko not_active Expired - Fee Related
- 2009-06-30 MX MX2010012692A patent/MX2010012692A/es active IP Right Grant
- 2009-06-30 JP JP2011516797A patent/JP5602729B2/ja not_active Expired - Fee Related
- 2009-06-30 HR HRP20140066AT patent/HRP20140066T8/hr unknown
- 2009-06-30 RU RU2011103207/04A patent/RU2505534C2/ru active
- 2009-06-30 EP EP09774296.9A patent/EP2318378B1/en active Active
- 2009-06-30 AU AU2009267136A patent/AU2009267136B2/en not_active Ceased
- 2009-06-30 SG SG10201604677RA patent/SG10201604677RA/en unknown
- 2009-06-30 SG SG201009559A patent/SG167561A1/en unknown
- 2009-06-30 SI SI200930832T patent/SI2318378T1/sl unknown
- 2009-06-30 PL PL09774296T patent/PL2318378T3/pl unknown
- 2009-06-30 WO PCT/US2009/049182 patent/WO2010002845A2/en not_active Ceased
- 2009-06-30 ES ES09774296.9T patent/ES2442946T3/es active Active
-
2013
- 2013-03-18 US US13/846,140 patent/US20130217661A1/en not_active Abandoned
- 2013-11-26 CY CY20131101057T patent/CY1114842T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0810206A2 (pt) | Método de tratar câncer | |
| BRPI1007477A2 (pt) | método, e, composição de tratamento de poço | |
| BRPI0906962A2 (pt) | Composto, e, composição farmacêutica | |
| BRPI0906556A2 (pt) | Composto, e, composição farmacêutica | |
| BRPI0814941A2 (pt) | Composição de tratamentode semente, e, método de tratamento de semente. | |
| BRPI0908100A2 (pt) | produto combinação, uso de um composto, e, método de tratar câncer | |
| EP2429987A4 (en) | AMIDE COMPOUND, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | |
| BRPI0919238A2 (pt) | métodos e composições para o tratamento de câncer | |
| BRPI0815057A2 (pt) | Composto, composição farmacêutica, e, método para tratar infecção. | |
| BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
| BRPI0922475A2 (pt) | composto, composição farmacêutica , método para tratar câncer, e, uso de um composto. | |
| BRPI1012892A2 (pt) | composto, e, composição farmacêutica. | |
| BRPI0917681A2 (pt) | Composto, e, composição farmacêutica | |
| BRPI0811589A2 (pt) | Composição farmacêutica e método para tratar câncer | |
| BRPI0910259A2 (pt) | métodos de tratamento de inflamação | |
| BRPI0919575A2 (pt) | método, e, composição | |
| CY2016053I1 (el) | Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας | |
| BRPI0909164A2 (pt) | método e composições para o tratamento de câncer | |
| BRPI0910854A2 (pt) | métodos de tratamento | |
| DK2121139T3 (da) | Formulations for cancer treatment | |
| BRPI0823277A2 (pt) | Composição, e , método | |
| BRPI0906094A2 (pt) | composto e método de tratamento de diabetes do tipo ii | |
| PT2200431T (pt) | Novos métodos e composições para o tratamento do cancro | |
| DK2254873T3 (da) | Benzodiazepinforbindelse og farmaceutisk sammensætning. | |
| BRPI0922884A2 (pt) | compostos para tratamento de câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/09/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 14A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2729 DE 25-04-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |